Pirfenidone: A novel antifibrotic agent with implications for the treatment of obliterative bronchiolitis

被引:18
作者
Dosanjh, AK [1 ]
Wan, B [1 ]
Throndset, W [1 ]
Sherwood, S [1 ]
Morris, RE [1 ]
机构
[1] Stanford Univ, Med Ctr, Stanford, CA 94305 USA
关键词
D O I
10.1016/S0041-1345(98)00478-3
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
引用
收藏
页码:1910 / 1911
页数:2
相关论文
共 8 条
[1]   CHARACTERIZATION OF THE CELLULAR REDUCTION OF 3-(4,5-DIMETHYLTHIAZOL-2-YL)-2,5-DIPHENYLTETRAZOLIUM BROMIDE (MTT) - SUBCELLULAR-LOCALIZATION, SUBSTRATE DEPENDENCE, AND INVOLVEMENT OF MITOCHONDRIAL ELECTRON-TRANSPORT IN MTT REDUCTION [J].
BERRIDGE, MV ;
TAN, AS .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1993, 303 (02) :474-482
[2]  
IYER SN, 1995, J LAB CLIN MED, V125, P779
[3]   Pirfenidone diminishes cyclophosphamide-induced lung fibrosis in mice [J].
Kehrer, JP ;
Margolin, SB .
TOXICOLOGY LETTERS, 1997, 90 (2-3) :125-132
[4]  
LURTON JM, 1996, AM J RESP CRIT CARE, V153, pA403
[5]  
MARGOLIN S, 1997, PIRFENIDONE INVESTIG
[6]  
Mauck KA, 1996, J HEART LUNG TRANSPL, V15, P709
[7]  
Schelegle ES, 1997, P SOC EXP BIOL MED, V216, P392
[8]  
WALLWORK J, 1994, CLIN TRANSPLANT, V8, P341